Diabetes And Oncology Drive Interest in China - Shanghai R&D Summit
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Pharma companies and investors are focusing their interest in China, as they are elsewhere, on diabetes and oncology, but they face unique challenges, according to panelists at a recent R&D conference in Shanghai
You may also be interested in...
China's Drug Regulators Issue Warning On Use Of Avandia While Debating Suspension Vs. Restricted Use
SHANGHAI - China's State FDA issued a warning Sept. 25 on the potential cardiovascular risk of using drugs containing rosiglitazone and told the public that the agency is organizing a committee of experts to evaluate the benefits and risks of rosiglitazone drugs, including GlaxoSmithKline's Avandia (rosiglitazone), Avandamet (metformin and rosiglitazone) and generics
China's Drug Regulators Issue Warning On Use Of Avandia While Debating Suspension Vs. Restricted Use
SHANGHAI - China's State FDA issued a warning Sept. 25 on the potential cardiovascular risk of using drugs containing rosiglitazone and told the public that the agency is organizing a committee of experts to evaluate the benefits and risks of rosiglitazone drugs, including GlaxoSmithKline's Avandia (rosiglitazone), Avandamet (metformin and rosiglitazone) and generics
China's Generic Companies Leaning Toward Innovation To Target Global Market: FT China Healthcare And Life Science Summit
SHANGHAI - While China reported a slowdown of its economic growth in the second quarter - 10.3 percent compared to 11.9 percent in the same year-ago quarter - many economists feared China was close to overheating, but the life science industry in China is still hot to global investors, and Chinese generics companies are evolving to become more integrated and innovative, according to speakers from the FT China Healthcare and Life Science Summit held in Shanghai July 13